Botulinum toxin type-A and plaster cast treatment in children with upper brachial plexus palsy.
OBJECTIVE
Electrical stimulation, physical therapy and occupational therapy remain the main treatment for children with upper brachial plexus palsy (UBPP), when surgery has been excluded. A pilot study was undertaken to investigate whether botulinum toxin type A (BoNT-A) and plaster casting, as adjunct to the physical therapy, decreased muscle contracture and improved the position and function of the impaired arm.


METHODS
Twenty-two children (mean age 5.6 +/- 3.4 years) with mild UBPP who previously underwent serial cast treatment, unsuccessfully, were enrolled. Neurological impairment and functional status were quantified using Medical Research Council (MRC) and Mallet scales and the Nine-Hole Peg Test (NHPT). Elbow extension was measured using a goniometer. Biceps brachii, brachialis, pronator teres and pectoralis major muscles were injected with 22 units kg(-1) BoNT-A (Dysport, Ipsen). After injection, the treated arm was fixed with a plaster cast and progressively lengthened over 14 days. The cast was maintained for 30 days. Assessments of elbow extension, MRC, Mallet Scale and NHPT were made at baseline, 3, 6 and 12 months.


RESULTS
After BoNT-A injection, children had significant improvement of active elbow extension (15.5 degrees +/- 17.1 at 12 months after injection, compared with 42.0 degrees +/- 10.4 at baseline; p < 0.001). NPHT scores improved significantly over the 12 months (51.1 +/- 21.8 seconds compared with 56.7 +/- 19.3 seconds at baseline, p < 0.01). MRC and Mallet scale scores of the paretic muscles were unchanged.


CONCLUSIONS
The children showed a reduction in muscular contracture and improvements of the arm position and elbow extension. The data support the use of BoNT-A and plaster casting as an adjunct to physical therapy, in the treatment of children with mild UBPP.
Basciani
M
M
Department of Rehabilitation, IRCCS, Casa Sollievo della Sofferenza, S. Giovanni Rotondo, FG, Italy.
Intiso
D
D
D000293:Adolescent; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D020516:Brachial Plexus Neuropathies / Q000503:physiopathology / Q000628:therapy*; D002370:Casts, Surgical; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003286:Contracture / Q000628:therapy*; D004185:Disability Evaluation; D004551:Elbow Joint / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D010865:Pilot Projects; D016059:Range of Motion, Articular
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A